Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Adaptimmune Therapeutics (ADAP) Shares March Higher, Can It Continue?

Adaptimmune Therapeutics plc ADAP has been on the move lately as the stock has risen by 14.3% in the past four weeks, and it is currently trading well above its 20-Day SMA. This is a pretty solid move higher, but the question that has to be on investors’ minds right now is; can this trend continue?

While there can be no telling for sure, it is certainly encouraging that earnings estimates have risen in the past few weeks on the company, suggesting that sentiment on ADAP is moving in the right direction. In fact, the stock currently has a Zacks Rank #2 (Buy), suggesting that the recent run could certainly continue for this in-focus company. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
ADAPTIMMUNE THR (ADAP): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research